Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Device Type Reclassification Urged As Alternative To EU Implant Proposal

This article was originally published in The Gray Sheet

Executive Summary

European member states should exercise their option to reclassify specific product types as an alternative to the wholesale reclassification of implants from Class IIb to Class III, EUCOMED maintains.

You may also be interested in...



EU Breast Implant Regulatory Upgrade Blazes Path For Other Reclassifications

European Union reclassification of breast implants from Class IIb to Class III will soon be under way

EU Breast Implant Regulatory Upgrade Blazes Path For Other Reclassifications

European Union reclassification of breast implants from Class IIb to Class III will soon be under way

EU Medical Devices Directive Review Invites Reclassification Requests

The European Commission is encouraging member states to use Article 13 of the Medical Devices Directive to submit requests for reclassification, rather than reforming the directive itself

Related Content

UsernamePublicRestriction

Register

MT015144

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel